A Phase 1 Study of NX-5948 in People With B-Cell Lymphoma/Leukemia

Full Title

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

Purpose

Researchers are seeking the best dose of NX-5948 for people with B-cell lymphoma or leukemia that keeps growing after treatment. Examples of these cancers include:

• Chronic lymphocytic leukemia
• Small lymphocytic lymphoma
• Diffuse large B-cell lymphoma
• Follicular lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Waldenstrom macroglobulinemia
• Primary central nervous system lymphoma

Drugs that block a protein called BTK are used to treat B-cell lymphoma and leukemia. Over time, however, these drugs may stop working. NX-5948 breaks down the BTK protein. It may work well against B-cell lymphomas and leukemias that are no longer responding to drugs that block BTK. NX-5948 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have B-cell lymphoma or leukemia that came back or keeps growing after treatment.
• Have recovered from the serious side effects of prior therapies before taking NX-5948.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Meghan Thompson’s office at 646-608-4253.